Clinical trial · Interventional
An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT)
A Phase II/III Study of Cyclotron-produced Tc-99m Pertechnetate (C-PERT) Efficacy and Safety in Patients With Conformed and Suspected Thyroid Cancer or Head and Neck Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study was not initiated
Summary
Brief summary (as posted)
Doctors at the Cross Cancer Institute have developed a new method of producing 99mTc Pertechnetate in a cyclotron unit. A study done at the Cross Cancer Institute in 2011 with ten patients using this imaging agent showed that it was safe and produced images with the same pattern as generator produced Pertechnetate. This study is now being done in larger numbers of patients to again show that the imaging pattern of both agents is the same, and to again demonstrate its safety.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Neoplasms | Head and Neck Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Thyroid Neoplasms | Thyroid Gland Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| C-PERT | Drug | — | UNRESOLVED |
| G-PERT | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- C-PERT
- description
- 45 patients with cancer
- interventionNames
- Drug: C-PERT
- type
- ACTIVE_COMPARATOR
- label
- G-PERT
- description
- 65 patients with cancer
- interventionNames
- Drug: G-PERT
Primary outcomes (1)
- measure
- To demonstrate the efficacy of C-PERT (manufactured by the Edmonton PET Centre/ERC) in comparison to G-PERT (fromm approved commercial sources) using qualitative and quantitative clinical imaging biodistribtion data.
- timeFrame
- 5 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 79 Years
Show eligibility criteria text
Inclusion Criteria: * thyroid cancer, or * Head and Neck cancer for salivary gland transfer * age 18-79 * biochemical parameters \< 5x ULN * WBC \> 3.0/uL * ANC \> 1.5/uL * platelets \> 75,000/uL * hemoglobin \> 10 g/dL * Karnofsky 50-100 Exclusion Criteria: * nursing or pregnant females * \< 18 or \> 79 Years * uncontrolled asthma * acute iritis * narrow angle glaucoma * previous radiation to head/neck
References
Publications (0)
Data not yet available